Clinical comparison between childhood upper urinary tract infection due to extended- and non-extended-spectrum β-lactamase-producing bacteria
-
- Nagata Hiroko
- Department of Pediatrics, Japanese Red Cross Kumamoto Hospital
-
- Furuse Akio
- Department of Pediatrics, Japanese Red Cross Kumamoto Hospital
-
- Irie Shinji
- Department of Pediatrics, Japanese Red Cross Kumamoto Hospital
-
- Kanou Kyoko
- Department of Pediatrics, Japanese Red Cross Kumamoto Hospital
-
- Kawasaki Tatsuya
- Department of Pediatrics, Japanese Red Cross Kumamoto Hospital
-
- Sawada Takaaki
- Department of Pediatrics, Japanese Red Cross Kumamoto Hospital
-
- Fukuoka Kahoru
- Department of Pediatrics, Japanese Red Cross Kumamoto Hospital
-
- Kourogi Kensaku
- Department of Pediatrics, Japanese Red Cross Kumamoto Hospital
-
- Kurata Hirofumi
- Department of Pediatrics, Japanese Red Cross Kumamoto Hospital
-
- Takaki Yuugo
- Department of Pediatrics, Japanese Red Cross Kumamoto Hospital
-
- Ohhira Tomoko
- Department of Pediatrics, Japanese Red Cross Kumamoto Hospital
-
- Mutou Yuuichirou
- Department of Pediatrics, Japanese Red Cross Kumamoto Hospital
-
- Nishihara Takahiro
- Department of Pediatrics, Japanese Red Cross Kumamoto Hospital
-
- Hirai Katsuki
- Department of Pediatrics, Japanese Red Cross Kumamoto Hospital
-
- Komatsu Nagisa
- Department of Pediatrics, Japanese Red Cross Kumamoto Hospital
-
- Migita Masahiro
- Department of Pediatrics, Japanese Red Cross Kumamoto Hospital
Bibliographic Information
- Other Title
-
- ESBL(Extended-spectrum β-lactamase)産生菌とESBL 非産生菌による上部尿路感染症の臨床的解析
Search this article
Description
This study retrospectively investigated the annual incidence, first-line antibiotic therapy, and risk factors for extended-spectrum β-lactamase (ESBL)-producing upper urinary tract infection (UUTI). The 166 cases of UUTI at our hospital from April 2009 to March 2013 were divided into 2 groups: UUTI due to ESBL-producing bacteria (group A, 28 cases), and UUTI due to non-ESBL-producing bacteria (group B, 138 cases). The bacteriuria in group A consisted of Escherichia coli (25 cases), Klebsiella oxytoca (2 cases), and K. pneumoniae (1 case). In both group A and B, the annual incidence of UUTI increased during the study period. Treatment antibiograms in group A showed that cefmetazole (CMZ), meropenem (MEPM), flomoxef (FMOX), imipenem/cilastatin sodium (IPM/CS), and amikacin (AMK) had 100% sensitivity. Twelve cases of ESBL-UUTI were resistant to the selected antibiotics. However, those patients were treated without changing antibiotics. The mean duration of intravenous antibiotic therapy in group A was significantly longer than in group B (8.0 vs. 6.0 days; P=0.001). There were no significant differences in age, sex, congenital anomalies of the kidney urinary tract or the number of cases treated with prophylactic antibiotics between groups. Our data suggest that the annual incidence of ESBL-UUTI is increasing; and in cases of UUTI, antibiotics against ESBL-producing bacteria should be considered.
Journal
-
- Japanese journal of pediatric nephrology
-
Japanese journal of pediatric nephrology 28 (1), 37-42, 2015
The Japanese Society for Pediatric Nephrology
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390282679317373312
-
- NII Article ID
- 130005102917
-
- ISSN
- 18813933
- 09152245
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- Crossref
- CiNii Articles
- OpenAIRE
-
- Abstract License Flag
- Disallowed
